FDA Approves Once-Monthly Injection for Opioid Addiction

Share this content:
FDA Approves Once-Monthly Injection for Opioid Addiction
FDA Approves Once-Monthly Injection for Opioid Addiction

FRIDAY, Dec. 1, 2017 (HealthDay News) -- Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Buprenorphine has been shown to reduce opioid withdrawal symptoms and the desire to use opioids, "without causing the cycle of highs and lows associated with opioid misuse or abuse," the FDA said.

Sublocade was evaluated in clinical studies involving 848 adults who were diagnosed with moderate-to-severe cases of opioid use disorder. The most common side effects included constipation, nausea, vomiting, headache, drowsiness, and injection-site pain. Sublocade's safety and effectiveness were not evaluated in individuals under age 17, the FDA said.

The maker of Sublocade -- Indivior -- is required to conduct additional studies to see if some patients could benefit from a dose of Sublocade that's higher than currently approved.

Indivior is based in the United Kingdom.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »